Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Company and personnel

19 June 2019

GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners

03 Jun 2019 - 06 Jun 2019

BIO International Convention, Philadelphia, PA (US)

24 April 2019

GenSight Biologics Reports Full Year 2018 Financial Results

23 April 2019

GenSight Biologics Reports its Cash Position as of March 31, 2019

25 February 2019

GenSight Biologics completes a capital increase of €8 million without discount subscribed entirely by Sofinnova

04 February 2019

GenSight Biologics Updates its 2019 Financial Calendar

25 Mar 2019 - 27 Mar 2019

BioEurope Spring, Vienna, Austria

23 January 2019

GenSight Biologics Announces its 2019 Financial Calendar

23 January 2019

GenSight Biologics Reports its Cash Position as of December 31, 2018

10 Jan 2019 - 11 Jan 2019

Oddo BHF Forum, Lyon, France

  • View previous 9 articles
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page